Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World May 28, 2014 Phillip Broadwith	Time called on Pfizer -- AstraZeneca deal Pfizer's pursuit of a pharmaceutical megamerger has concluded with the US giant withdrawing its final offer two hours before the deadline set by the UK's takeover rules.
Chemistry World March 26, 2014 Phillip Broadwith	AstraZeneca boosts open innovation efforts Astrazeneca has launched a new web portal, bringing together new and existing open innovation programs. The aim is to make collaboration with academics, other companies, governments and non-government organizations easier.
Chemistry World April 3, 2014 Emma Stoye	Pharma giants plan new public--private collaborations AstraZeneca will partner with the Medical Research Council, in its new Cambridge site, while the Wellcome Trust Genome Campus will host a new center for target validation studies, jointly founded with the European Bioinformatics Institute and GlaxoSmithKline.
Chemistry World April 29, 2014 Phillip Broadwith	Pfizer courts AstraZeneca megamerger US-based pharma behemoth Pfizer has publically announced its intention to make a merger offer to the UK's AstraZeneca, in a deal valued at around $100 billion.
Chemistry World June 19, 2013 Laura Howes	AstraZeneca announce new UK hub The new hub will consolidate all of AZ's UK activities, including biologics arm MedImmune, at the Cambridge Biomedical Campus on the southern outskirts of the city.
Chemistry World May 22, 2007 James Mitchell Crow	Scientists Seek Indicators of Illness A 17 million-pound fund has been set up by the UK's Medical Research Council for research into biomarkers, the tell-tale body chemicals that are associated with particular diseases.
Chemistry World January 30, 2014 Phillip Broadwith	AstraZeneca ends R&D in India Pharmaceutical firm AstraZeneca is quitting its R&D site in Bangalore, India.
Chemistry World February 2, 2015 Emma Stoye	UK announces 40m fund for synthetic biology The UK government has said it will invest 40 million pounds in synthetic biology over the next five years, 32 million of which will be used to establish three new research centers.
Chemistry World May 14, 2014 Andy Extance	Pfizer presses hard for AstraZeneca deal US pharma giant Pfizer is battling a backlash of suspicion and hostility across the world over its attempts to acquire its UK-headquartered rival AstraZeneca.
Chemistry World May 31, 2013 Phillip Broadwith	Japanese pharma opens compound vaults Japanese pharmaceutical companies are opening up their libraries of experimental compound as part of a new partnership program. The initiative aims to find new drugs for malaria, tuberculosis and neglected tropical diseases.
Chemistry World May 19, 2014 Phillip Broadwith	AstraZeneca refuses Pfizer's 'final' offer The US giant has described this proposal, valuing AZ at 70 billion pounds, as 'final' and says it 'cannot be increased'.
Chemistry World March 19, 2013 Simon Hadlington	Global AstraZeneca restructuring will cost 1600 jobs The company's global research blueprint will now be centered on the creation of three 'strategic R&D centers' for small molecules and biologics, to be based in Cambridge in the UK, Gaithersburg in Maryland, US, and Molndal in Sweden, to be completed by 2016.
Chemistry World May 31, 2009 Nina Notman	The natural approach to winning at drug discovery High throughput drug screening is often described as a casino, with the odds stacked on the side of success as long as a big enough library is used.
Chemistry World May 28, 2008 Mark Peplow	Cancer research gets collaborative funding boost In an effort to crack some of the biggest problems in cancer drug discovery, Cancer Research UK has launched a unique funding program that promises to help bridge the gap between fundamental research and big pharma pipelines.
The Motley Fool October 21, 2005 Stephen D. Simpson	Is Wyeth Your Happy Pill? The pharma has crawled back from scandal, but growth prospects aren't looking so healthy. Investors should not be in a hurry to pay a premium for these shares today.
Chemistry World February 2, 2011 Andy Extance	Pfizer to close historic UK site Most of the 2400 people employed at the Pfizer site in Sandwich, UK, will be made redundant over the next 18-24 months as the US pharma giant restructures its research operations.
Chemistry World February 2, 2012 Andrew Turley	AstraZeneca to cut 7300 more jobs UK drugmaker AstraZeneca has announced plans to cut a further 7300 jobs to make annual savings of $1.6 billion by the end of 2014, a move that will cost the company $2.1 billion in the near term.
Chemistry World September 8, 2010 Andrew Turley	Vince Cable: science cuts are coming Taxpayers should only back research that makes money or is academically exceptional, UK business secretary Vince Cable said today in his first speech on science.
The Motley Fool June 2, 2009 Brian Orelli	ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies.
Chemistry World March 16, 2007	Testing Times for 'Mega-Pharma' A stern warning and gloomy forecast were delivered to the pharmaceutical industry at the Drug Discovery and Technology Summit in London.
Pharmaceutical Executive February 1, 2006 Alana Klein	Thought Leader: Q&A with Ed Broughton Eisai executive Ed Broughton discusses new business opportunities, and what types of partnerships are up next for the growing pharmaceutical company.
Chemistry World March 2011 Bea Perks	Editorial: At the forefront The news that most of Pfizer's 2400 employees at Sandwich, U.K. will be made redundant over the next two years was met with surprise, disappointment and anger.
Chemistry World July 2008 Kevin Rogers	What future for small molecule therapy? Pharmaceutical companies overlook bench chemists at their peril
Chemistry World May 7, 2013 Phillip Broadwith	AstraZeneca site to become biotech hub The first three companies have already moved in, and more will hopefully follow to fill the space left by AZ as it relocates to Cambridge, UK.
The Motley Fool May 25, 2007 Brian Orelli	Amylin Sifts for Gold The biotech mines extra value from its compound library. Investors, take note.
Chemistry World July 31, 2014 Phillip Broadwith	AstraZeneca stocks respiratory and cancer pipelines AstraZeneca has agreed to buy Spanish firm Almirall's respiratory drug assets for $875 million up front, plus up to $1.2 billion in performance milestone payments.
The Motley Fool October 18, 2005 Stephen D. Simpson	More Good News From Novartis This Swiss drug giant continues to post steady growth. Investors, take note.
Chemistry World September 17, 2007	Uk Pharma Shifts Manufacturing Overseas Drug firm AstraZeneca has today reiterated that it will outsource drug manufacturing.
The Motley Fool August 8, 2007 Brian Lawler	Array's Bright Pipeline Array BioPharma announces its goals for the months ahead in its fourth-quarter results. What is interesting is the varied mix of new compounds in their pipeline.
The Motley Fool December 19, 2005 Stephen D. Simpson	Pfizer Wins, a Sector Rejoices The pharmaceutical dodges a bullet and investors find renewed enthusiasm for big-cap pharma.
The Motley Fool May 4, 2006 Stephen D. Simpson	AstraZeneca Snuffs Out Galida Will any of the new dual-PPAR drugs make it to the market? Here's another good reminder for pharmaceutical and biotech investors that you shouldn't count your chickens until the FDA has let them hatch.
The Motley Fool March 26, 2009 Brian Orelli	Big Pharma's R&D Model Is Broken Bigger isn't always better.
The Motley Fool November 26, 2007 Brian Lawler	Glaxo Goes Holiday Shopping The pharmaceutical giant snaps up another acquisition, privately held Reliant Pharmaceuticals, for $1.65 billion in cash, one of the largest pharma deals of the year.
Chemistry World September 2009	Education and wealth It seems that the UK government is interested in answering the question: what return does the UK get for the money it puts into academic research in chemistry?
Chemistry World August 3, 2012 Andrew Turley	Pfizer secures Sandwich buyer Pfizer has found a buyer for its R&D site in Sandwich, UK: the site -- now called Discovery Park -- has been bought by a private consortium, according to Kent County Council.
Chemistry World March 20, 2008 Richard Van Noorden	UK Drug Firms to Slash Research and Jobs The UK pharmaceutical industry is expecting to cut jobs and investment in R&D following an alarming slump in confidence in the UK market.
Chemistry World November 26, 2015 Rebecca Trager	Drug firms to share chemical compound libraries Anglo-Swedish pharmaceutical firm AstraZeneca and French drug company Sanofi have agreed to exchange 210,000 chemical compounds from their respective proprietary libraries.
Chemistry World May 20, 2015 Katrina Kramer	Taking the lead on drug discovery Researchers from the UK have developed a straightforward strategy for making compounds that have the potential to become clinical drugs.
Chemistry World January 20, 2014 David Bradley	Molecular librarians create druglike collections Finding biologically active small molecules with pharmaceutical potential is a bittersweet process. Now, a new approach to building libraries of diverse alkaloid-type structures has been developed by US chemists.
The Motley Fool January 26, 2006 Stephen D. Simpson	Will New Drugs Gild Lilly? Although Lilly's late-stage pipeline is weak, newer drugs should still be able to grow. Investors, this is still a mediocre investment option.
Chemistry World April 16, 2010 Sean Milmo	Ineos starts UK chemicals exodus Ineos's decision to relocate its headquarters to Switzerland because of corporate taxation concerns may spark an exodus of chemical and pharmaceutical companies from having their headquarters in the UK.
Chemistry World March 2, 2015 Phillip Broadwith	AstraZeneca to spin off anti-infectives research The new company's principal asset will be the novel gyrase inhibitor AZD0914, which is currently in Phase II clinical trials for treating gonorrhea.
Pharmaceutical Executive December 1, 2011	UK Report: Keep Calm and Carry On ... Differently Even as the global economic roller coaster affects one of the country's dearest public institutions, the National Health Service, there is still reason for optimism in these times of austerity.
The Motley Fool December 21, 2010 Brian Orelli	4 Drugmakers, 5 Deals, Christmas Is Here It looks like there were a lot of people in the business development offices at pharmaceutical companies looking to get their work done before taking off for the holidays. Check out all the deals that were announced yesterday.
The Motley Fool March 29, 2007 Brian Lawler	Genentech Going Forward Genentech gives guidance for first-quarter sales numbers. Investors, take note.
Chemistry World November 1, 2011 Sarah Houlton	A Shot in the Arm for Drugs for Neglected Diseases A new consortium of public and private sector partners has been launched by the World Intellectual Property Organization. Its aim is to share intellectual property that may help find drugs for malaria, tuberculosis and other neglected tropical diseases.
Chemistry World February 12, 2014 Manisha Lalloo	Synthetic strategy targets 'undruggable' small RNAs Chemists in the US have found a way to predict small molecules that can target short pieces of RNA involved in some diseases, such as cancer.
Chemistry World October 1, 2012 Andrew Turley	Pharma should 'double output by 2022' The President's Council of Advisors on Science and Technology advises that pharmaceutical companies should set a goal of doubling output of 'innovative new medicines that meet critical public health needs' over the next 10 -- 15 years.
The Motley Fool April 19, 2006 Brian Gorman	Pfizer Inches Forward The pharma continues on cost-cutting and gives back to shareholders, but R&D productivity remains a tough challenge.
The Motley Fool June 29, 2007 Brian Lawler	Genentech's All Good The biotech's latest partnership deal is nothing to worry about. Investors, take note.